Conference Year
Conference Month

Upcoming MDPI Conferences (3)

28 June 2023 Cancers Webinar | Bone Metastasis in Breast Cancer


Approximately 70–80% of patients with late-stage breast cancer will develop bone metastasis. This condition is currently considered incurable, and the life expectancy of these patients is around 2–3 years following diagnosis of bone involvement. Currently, we do not know which tumors are likely to progress to bone metastasis. Therefore, patients do not receive treatment until the metastasis is established and often quite large. There is a need to identify biomarkers that can be used to identify high-risk patients, enabling early intervention which could facilitate better outcomes.

When tumors arrive in bone, they become home to a metastatic niche which is made up of the endosteal niche (osteoblasts and hematopoietic stem cells) and the peri-vascular niche. Once in the niche, tumor cells can remain dormant for many years before being activated to form overt metastasis. Activation of dormant tumor cells is believed to be driven by factors that lead to the expansion of the metastatic niche, activation of cancer stem cells and/or suppression of immune regulatory mechanisms. Once tumors start to grow, tumor cells secrete factors such as PTHrP and TNF which stimulate activity of osteoclasts. Increased osteoclast activity leads to an increase in bone resorption resulting in osteolytic lesions and the release of bone-bound factors including TGFB which further increase tumor growth. This process is known as the vicious cycle of bone metastasis. Our current understanding of the processes that regulate tumor dormancy is still in its infancy. This, coupled with the complexity of tumor cell–bone cell interactions that take place during tumor growth in bone and the unique, hypoxic, immune-suppressed environment found in bone has hampered the development of more effective treatments for patients with this condition.

At the current seminar, we will highlight some of the exciting, novel work that is currently being carried out by bone metastasis experts to address pertinent gaps in our knowledge. We will investigate how miRNAs are being used to develop biomarkers for predicting the future recurrence of breast cancers in bone. Subsequently, we will explore detailed intra-vital imaging methodologies that are being used to track tumor cells as they move into the bone and lodge in the metastatic niche. We will then investigate the role of IL-1B signaling in the regulation of tumor cell dormancy before looking at new ways to improve the efficacy of immunotherapies for treating breast cancer bone metastasis.

Date: 28 June 2023 at 2:00 p.m. CEST | 8:00 a.m. EST | 8:00 p.m. CST Asia
Webinar ID: 813 4269 9012

Register now for free!

Speaker/Presentation Time in CET Time in EST
Prof. Dr. Penelope Dawn Ottewell
Chair Introduction
2:00–2:10 p.m. 8:00–8:10 a.m.
Prof. Dr. Philippe Clézardin
The Role of miRNAs in Promoting Breast Cancer Bone Metastasis
2:10–2:40 p.m. 8:10–8:40 a.m.
Dr. Michelle McDonald
Intravital Imaging of Bone Targeting Cancers
2:40–3:10 p.m. 8:40–9:10 a.m.
Prof. Dr. Penelope Dawn Ottewell
IL-1B Driven Regulation of Breast Tumor Cell Dormancy in Bone
3:10–3:40 p.m. 9:10–9:40 a.m.
Dr. Rachelle Whitney Johnson
Immune Cell Regulation of Breast Cancer Bone Metastasis
3:40–4:10 p.m. 9:40–10:10 a.m.
Q&A Session 4:10–4:40 p.m. 10:10–10:40 a.m.
Prof. Dr. Penelope Dawn Ottewell
Closing of Webinar
4:40–4:50 p.m. 10:40–10:50 a.m.

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? You are still encouraged to register, and we will let you know when the recording is available to watch.

Webinar Chair and Keynote Speakers:

  • Prof. Dr. Penelope Dawn Ottewell, Department of Oncology and Metabolism, University of Sheffield, UK;
  • Prof. Dr. Philippe Clézardin, INSERM, Research Unit UMR_S1033, LyOS, Faculty of Medicine Lyon-Est, France;
  • Dr. Michelle McDonald, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia;
  • Dr. Rachelle Whitney Johnson, Program in Cancer Biology, Vanderbilt University, USA.

Relevant Special Issue:
Bone Metastasis in Breast Cancer
Guest Editor: Prof. Dr. Penelope Dawn Ottewell

Submission Deadline: 1 August 2023

15–30 November 2023 The 27th International Electronic Conference on Synthetic Organic Chemistry


We are pleased to announce that the 27th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-27), chaired by Dr. Julio A. Seijas, will be held online from 15 to 30 November 2023 at

ECSOC-27 aims to provide leading scientists working in selected fields with a robust common platform on which to share and discuss the latest research and promote the advancement of exciting and rapidly changing research. This online conference will make your presentation accessible to hundreds of researchers worldwide, with active engagement of the audience in question-and-answer sessions and discussion groups that will take place online.

The conference has been divided into five themes. Please submit your articles as soon as possible, indicating which theme best fits your submission.

S1. General Organic Synthesis
S2. Bioorganic, Medicinal and Natural Products Chemistry
S3. Microwave Assisted Synthesis
S4. Polymer and Supramolecular Chemistry
S5. Computational Chemistry

During the conference, you can upload papers, posters, and presentations (including videos), comment on other presentations, and engage with fellow scholars in real-time. In this way, the conference offers a novel opportunity to exchange opinions and views within the scholarly community and to discuss the papers and latest research in a discussion forum.

We hope you will be able to join this exciting event, which is organized and sponsored by MDPI, a scholarly open access publisher (, and the journal Molecules (ISSN: 1420-3049, Impact Factor 4.927 (2021)).

Paper Submission Guidelines:

All accepted proceedings papers will be published in one dedicated volume in the MDPI Proceedings journal  Chemistry Proceedings (ISSN 2673-4591). The publication of proceedings papers is free of charge.

For more information about the procedure for submission, peer review, revision, and acceptance of conference proceedings papers, please refer to the section “Instructions for Authors” at

Abstract Submission Deadline: 15th September 2023
Abstract Notification Deadline: 20th September 2023
Full Paper Submission Deadline: 30th September 2023
Conference Time: from 15th to 30th November 2023

We look forward to receiving your research papers and welcoming you to the 27th edition of the e-conference.

1–15 December 2023 The 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV 2023)


Dear scientists, researchers, and authors,

We are pleased to announce that the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV 2023), chaired by Prof. Dr. François Meurens and Dr. Fanny Renois, will be held from 1 to 15 December 2023.

This year, the sessions of interest for this event include, but are not limited to, the following:

S1. COVID-19 Vaccines and Vaccination.
S2. Vaccines against Infectious Diseases.
S3. Vaccines and Society.

We proudly invite you to join IECV 2023 to present your latest vaccine research and developments as well as share novel ideas on related topics.

You can participate in IECV 2023 free of charge in the following two ways:

- Submit Abstracts and Proceedings/Supplementary Files
Submit an abstract before 11th July 2023. After acceptance, you will be asked to submit a short proceedings paper (three–six pages), a poster, a slide presentation (in PDF form), and/or a short video presentation (max. three–five minutes) before 13th September 2023. Detailed information: Instructions for Authors.

- Attend Live Sessions
During the duration of the conference a number of live online sessions will be programmed. We are pleased to invite you to subscribe to IECV 2023 at so that you can receive email notifications when the live session program is online and open online discussion.

For more information about the procedures for the submission, peer review, revision, and acceptance of conference proceedings papers, please refer to the “Instructions for Authors” section at

- Conference Awards
Best Paper Award (CHF 500) and Best Presentation Award (CHF 500). For details, please refer to

We will provide Accepted Submission Certificates to authors whose abstracts and conference proceedings or presentation files have been accepted and published. We also provide Participation Certificates to authors who attend live sessions.

Abstract submission deadline: 11th July 2023.
Notification of acceptance deadline: 25th July 2023.
Proceedings paper submission deadline: 13th September 2023.
Conference: 1–15 December 2023.

We look forward to receiving your research papers and welcoming you to this e-conference.

Please do not hesitate to contact us if you have any questions.

Cancers announces selected third-party conferences. In case you would like to announce your own event on the Cancers website, please fill out the following form to apply for the announcement of a conference or other academic event (seminar, workshop).

Conference Year
Conference Month

Upcoming Partner Conferences (5)

28–30 June 2023 The Annual Scientific Meeting of British Gynaecological Cancer Society

Aberdeen, UK

This one-day meeting, taking place at the Suttie Centre at the University of Aberdeen will include a series of live surgical procedures, informal presentations, interactive debates, audience discussions and equipment/technology demonstrations.

The primary objectives of the BSGOG are to focus on surgical procedures, surgical techniques, surgical training/education, surgical innovations including surgical equipment and novel technologies in addition to developing and promoting surgical trials. There will be a real-time two-way audio-visual link-up to live surgeries including a robotic radical hysterectomy and discussions on the RACC Trial by Henrik Falconer, Karolinska Institute, Sweden, and an open C2 nerve-sparing radical hysterectomy from Mustafa Muallem, Charite Hospital, Berlin, Germany. Conference Chairs include Christophe Pomel and Christina Fotopoulou. The conference is also greatly honoured to be endorsed by ESGO, the European Society of Gynaecological Oncologists.

We strongly advise you to register as soon as possible as there are limited spaces available.

Please note, the live surgical cases will be finalised a few days before the session depending on availability and suitability.

We hope to see you in the “Granite City” of Aberdeen.

7–9 September 2023 The 17th Edition of the ILCA Annual Conference

Amsterdam, The Netherlands

The 17th edition of the ILCA Annual Conference will take place in Amsterdam on 7th–9th September 2023. 

ILCA AC23 is a must-attend multidisciplinary gathering for liver cancer experts where you can expect state-of-the-art lectures, cutting-edge symposia and the ILCA Tumor Board. You will get the chance to exchange knowledge and insights with top experts on hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) while enjoying Amsterdam's unique charm and range of networking opportunities. In addition, this year's conference program will be enriched with a focus on NASH-related HCC and advanced spatial omics technology for a better understanding of the tumor microenvironment and management of HCC in the new era. It really is a conference not to miss! 

Discover more here:

9–12 September 2023 The 34th IASGO World Congress: WEAVING THE FUTURE

Verona, Italy

IASGO stands for the International Association of Surgeons, Gastroenterologists and Oncologists. IASGO was founded in 1988, and today, it has more than 1700 members from over 90 countries worldwide.

The mission of this organization is the globalization of medical knowledge and expertise through a well-structured system of continued medical education. IASGO believes that medical knowledge and expertise belong to every human being and that this knowledge must be available beyond discrimination—on individual, institutional or national levels—for every patient fighting for survival from challenging and life-threatening diseases.

We are currently experiencing an era of transition with significant innovations. Exciting scientific and technological advances are changing all areas of our lives. The recent emergency linked to the COVID-19 pandemic has inevitably played the role of an accelerator by increasing society’s focus on health issues. As a result, new technologies and medical therapies are emerging for many diseases.

At the IASGO 2023, we will discuss recent developments in surgical oncology to improve patient care and quality standards. Molecular biology and biotechnology are also revolutionizing medicine. The management of cancers is changing through the characterization of tumor molecular biological profiles using next-generation sequencing. The future of medicine is increasingly taking shape with the latest discoveries in genetics that enable promising new directions in oncological therapies.

Understanding the specific disease in each cancer patient has evoked a paradigm shift in oncology and is now opening new horizons in diagnostics and therapeutics. Progress is being made in the development of molecularly targeted therapy. Precision medicine aims to design and optimize the pathway for early diagnosis, assessing prognosis and tailoring therapeutic interventions. Furthermore, artificial intelligence algorithms can now successfully predict the risk of cancers and gastrointestinal diseases.

Increasingly more evidence suggests that lifestyle plays a fundamental role in well-being and patients’ health. Normal body weight and consistent physical activity prevent gastrointestinal, metabolic and neoplastic diseases and manage their presence. Likewise, proper nutrition counteracts chemotherapy’s side effects and helps toward a faster recovery after surgery, as demonstrated in the ERAS Society guidelines, with which IASGO cooperates.

The newly established IASGO multidisciplinary clinical trial consortium for the treatment of oncological diseases seeks to improve diagnosis and increase treatment feasibility and efficacy. It also aims to make the available treatments more accessible, improve patients’ quality of life and compliance with therapies and follow-up, and thus optimize the use of resources.

Finally, sustainability is becoming increasingly important in medicine and healthcare. Physicians need to be aware of eco-friendly solutions that provide high-quality care to patients while lowering costs and reducing the environmental impact. Prevention, telemedicine counseling, training and expanding healthcare coverage equitably should be the way forward.

For all these reasons and more, please join us at the upcoming IASGO Congress held at the Palazzo Della Gran Guardia in Verona between 9 and 12 September 2023. Verona is a spectacular city, a key part of Italian history, a symbol of art and culture in the world and a recognized UNESCO heritage site. We look forward to seeing you at this celebration of the latest medical and scientific advancements in GI cancer treatment during the IASGO 34th World Congress in the beautiful and traditional city of Verona.



20–22 September 2023 The First International Congress on “Update on the Management of Head and Neck Paragangliomas” 2023

Piacenza, Italy

The “Gruppo Otologico” ( is pleased to announce the organization of the First International Congress on “Update on the Management of Head and Neck Paragangliomas” (  for 20–22 September 2023, in Piacenza, Italy, an ancient city of Northern Italy near Milan which is the main seat of “Gruppo Otologico”. 

Head and neck paragangliomas are rare tumors that, due to anatomic location, pose significant challenges to surgical treatment. Nevertheless, the last 25 years have witnessed a significant evolution in surgical techniques, particularly in skull base surgery, which today makes operable tumors previously regarded as inoperable.

These exciting developments are enhanced by major advances in diagnostic and interventional radiology that vastly improve diagnosis, staging, and follow-up and pave the way for precision radiotherapy and locoregional disease control.

Furthermore, breakthroughs in genomics, proteomics, and metabolomics, which took off in the early 2000s, resulted in an ever-increasing understanding of the molecular processes that lie at the basis of head and neck paraganglioma and of paragangliomas at large.

With the organization of this congress, “Gruppo Otologico” aims to bring together for the first time the full range of health professionals and researchers from different specialties who work on head and neck paragangliomas.

The congress intends to address the state of the art of diagnosis, treatment, and follow-up, evaluate new research perspectives, and provide a highly specialized forum for the exchange of ideas and for the creation of networks to fight this neglected tumor type.

The Special Issue of Cancers will spread up-to-date information coming from the Congress to the global clinical and research community, to improve the global understanding and management of these complex and rare neoplasms. Relevant papers from authors who could not attend in person will be also considered for the Congress collection.

9–11 November 2023 The SIOG Annual Conference 2023

Valencia, Spain

Advancing age is a high-risk factor for cancer, with individuals over 65 accounting for 60% of newly diagnosed malignancies and 70% of all cancer deaths. As oncologists around the world shift their focus to the field of geriatrics, an increased understanding of the impact of research, innovation and clinical practices for older adults with cancer is becoming of critical importance. The International Society of Geriatric Oncology, also called SIOG (French acronym for Société Internationale d’Oncologie Gériatrique), is a not-for-profit organisation founded in the year 2000 and registered in Switzerland. SIOG is a multidisciplinary medical society of doctors and allied health professionals with expertise in oncology, geriatrics and supportive care. SIOG counts members in more than 84 countries around the world.

The SIOG Annual Conference is the only geriatric oncology conference for health professionals involved in the treatment of older cancer patients. Over the past few years, we have now gone beyond the challenge of convincing the international community that cancer in ageing populations deserves the attention and support to strengthen education, clinical practice and research for the global ageing population with cancer. SIOG is now a multidisciplinary community with members from highly diverse backgrounds, all working for older patients with cancer. The SIOG Annual Conference is a place where researchers, health care professionals and industry partners gather from across the world to discuss the latest in cancer for older patients.

Today, all oncologists are considered as geriatric oncologists. Geriatric oncology is no longer a niche field with only a few dedicated researchers and clinicians. SIOG is one of the leading societies channelling the knowledge and foresights of professionals to help determine the top priorities and actions to enhance the effectiveness of including geriatric protocols in the treatment and care of cancers of the elderly patients. Our conference delegates leave with new ideas and skills to improve their clinical practices and research methodologies, with an enhanced professional network and added value to their works.

The benefits of supporting the SIOG Annual Conference will include the following:

  • Exposure to 500+ oncologists, researchers, clinical practitioners, geriatricians, radiologists, psychologists, nutritionists, nurses and other healthcare professionals serving older cancer patients.
  • Increase the brand awareness of your company.
  • Discussion of news and current trends and developments for cancer in ageing populations.
  • Learn/identify expected future trends and necessary developments in the field of geriatric oncology.


Back to TopTop